ContraFect Corporation Announces Poster Presentation at the ICAAC/ICC 2015 Meeting for CF-301 for the Treatment of Staph Aureus Infections, Including MRSA
September 09, 2015 07:00 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - Sep 9, 2015) - ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a clinical-stage biotechnology company focused on the discovery and development of...
ContraFect Appoints Key Business Executives
September 08, 2015 07:00 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - Sep 8, 2015) - ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a clinical-stage biotechnology company focused on the discovery and development of...
FDA Grants Fast Track Designation to ContraFect's CF-301, the First of Its Lysins, Currently in Development for the Treatment of Staph Aureus Infections, Including MRSA
August 17, 2015 07:00 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - Aug 17, 2015) - ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a clinical-stage biotechnology company focused on the discovery and development of...
ContraFect Corporation Announces Second Quarter 2015 Financial and Operating Results
August 13, 2015 06:30 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - Aug 13, 2015) - ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ)
Initial Clinical Trial Program Advancing for New Class...
ContraFect Corporation Provides Update on CF-301 Phase 1 Trial
August 11, 2015 07:00 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - Aug 11, 2015) - ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a clinical-stage biotechnology company focused on the discovery and development of...
ContraFect Corporation to Announce Second Quarter 2015 Results on August 13, 2015
August 06, 2015 07:00 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - Aug 6, 2015) - ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a clinical-stage biotechnology company focused on the discovery and...
ContraFect Corporation Announces Issuance of Key Patent Covering Novel Lysin Technology
July 17, 2015 07:00 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - Jul 17, 2015) - ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on the discovery and development of protein...
ContraFect Corporation Announces $20,000,000 Private Placement
June 11, 2015 16:05 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - Jun 11, 2015) - ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on the discovery and development of protein...
ContraFect Corporation Announces First Healthy Volunteer Dosed With CF-301
May 21, 2015 06:30 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - May 21, 2015) - ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on the discovery and development of protein...
ContraFect Corporation Adds Former Cubist Executive Steven C. Gilman, PhD, to Board of Directors as Executive Chairman
May 20, 2015 06:30 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - May 20, 2015) - ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on the discovery and development of protein...